Abstracts Archive - Page 1690 of 2607 - ACR Meeting Abstracts

Abstract Number: 1361 • 2016 ACR/ARHP Annual Meeting
The Role of Von Willebrand Factor Antigen As a Disease Biomarker in the Clinical Assessment of Children with Juvenile Dermatomyositis
Dawn Wahezi¹, Vito Arena², Jaeun Choi² and Qi Gao², ¹Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: With the advent of new therapies, outcomes for children with juvenile dermatomyositis (JDM) have significantly improved. Accurate markers of clinically inactivedisease are thus fundamental…
Abstract Number: 1362 • 2016 ACR/ARHP Annual Meeting
Associations Between 25-Hydroxyvitamin D, Parathyroid Hormone, and Cathelicidin Concentrations with Inflammation and Cardiovascular Risk in Subjects with Pediatric Systemic Lupus Erythematosus
Varsha Gupta¹, Vin Tangpricha², Eric Yow³, Grace McComsey⁴, Laura E. Schanberg⁵, Angela B. Robinson⁶ and APPLE Investigators Group, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Biostatistics, Duke Clinical Research Institute, Durham, NC, ⁴Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ⁵Department of Pediatrics, Duke University Medical Center, Durham, NC, ⁶Pediatric Rheumatology, Rainbow Babies and Childrens Hospital, Cleveland, OH
Background/Purpose: Previous studies have shown associations between reduced serum 25-hydroxyvitamin D (25OHD) levels, inflammation, and disease activity in pediatric systemic lupus erythematosus (pSLE). The goal…
Abstract Number: 1363 • 2016 ACR/ARHP Annual Meeting
Serum Adipokines in Juvenile Dermatomyositis Are Associated with Disease Activities and Cardiac Function
Birgit Nomeland Witczak¹, Kristin Godang², Thomas Schwartz³, Nicoleta Cristina Olarescu⁴, Berit Flatø^5,6, Jens Bollerslev^5,7, Ivar Sjaastad^5,8,9 and Helga Sanner^5,6, ¹Oslo University Hospital, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Department of Specialised Endocrinology, Oslo University Hospital, Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ³Department of Infectious Diseases, Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁵Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁷Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁸Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁹Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: We have earlier demonstrated redistribution of adipose tissue in JDM patients. There is an increase in visceral adipose tissue (VAT), a highly active metabolic…
Abstract Number: 1364 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients
Raquel Campanilho-Marques^1,2,3,4, Claire Deakin⁵, Stephanie Simou⁶, Lucy R Wedderburn^2,7,8, Clarissa Pilkington^7,9 and on behalf of Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, ²Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ³Rheumatology, Santa Maria Hospital, CHLN, Lisbon, Portugal, ⁴Rheumatology, Instituto Português de Reumatologia, Lisbon, Portugal, ⁵Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ⁶Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁷Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Some patients with juvenile dermatomyositis (JDM) have a disease course which is refractory to multiple drug treatments. There is evidence that prolonged disease activity…
Abstract Number: 1365 • 2016 ACR/ARHP Annual Meeting
Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, Nastaran Bayat², Michael Ward³, Adam Huber⁴, Lan Wu¹, Gulnara Mamyrova⁵, Ira Targoff⁶, William Warren-Hicks⁷, Frederick W. Miller², Lisa G. Rider⁸ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴IWK Health Centre, Halifax, NS, Canada, ⁵Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC, ⁶VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Social and Scientific Systems, Inc., Durham, NC, ⁸Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with characteristic rashes and chronic muscle inflammation. Because of its rarity, most therapeutic choices are based…
Abstract Number: 1366 • 2016 ACR/ARHP Annual Meeting
Evidence Based Criteria for Corticosteroid Tapering/Discontinuation. an Analysis of the Paediatric Rheumatology International Trials Organization (PRINTO) Trial in New Onset Juvenile Dermatomyositis
Gabriella Giancane¹, Claudio Lavarello¹, Angela Pistorio¹, Francesco Zulian², Bo Magnusson², Tadej Avcin², Fabrizia Corona², Valeria Gerloni², Serena Pastore², Roberto Marini Sr.², Silvana Martino², Anne Pagnier², Michel Rodiere², Christine Soler², Valda Stanevicha², Rebecca ten Cate², Yosef Uziel², Jelena Vojinovic², Angelo Ravelli², Alberto Martini² and Nicolino Ruperto², ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Corticosteroids in juvenile dermatomyositis (JDM) alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represent the first-line treatment option for…
Abstract Number: 1367 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study
Sam Serafi¹, Vladislav Tsaltskan², Anna Yakovleva³, Heidi Sami¹, Frederick W. Miller⁴, Rodolfo Curiel¹, Olcay Y. Jones^1,5 and Lisa G. Rider^1,4, ¹Rheumatology, George Washington University, Washington, DC, ²Internal Medicine, George Washington University, Washington, DC, ³Department of Microbiology, Immunology, and Tropical Medicine., George Washington University, Washington, DC, ⁴Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ⁵Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: To investigate the long-term outcomes and prognostic factors for pts with juvenile-onset idiopathic inflammatory myopathies (JIIM) who are currently adults. Methods: Adults with JIIM…
Abstract Number: 1368 • 2016 ACR/ARHP Annual Meeting
Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease
Edward J. Oberle^1,2, Dominic O. Co^3,4, Yvonne Chiu^3,4, Michelle Bayer^4,5, Adam Huber⁶, Hatice Ezgi Baris⁷ and Susan Kim⁸, ¹Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Pediatrics, Ohio State University, Columbus, OH, ³Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁴Children's Hospital of Wisconsin, Milwaukee, WI, ⁵Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁷Boston Children's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of the skin and striated muscle. A subset of patients can present with rash only, labeled…
Abstract Number: 1369 • 2016 ACR/ARHP Annual Meeting
Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Takayuki Kishi², Nastaran Bayat², Ira N. Targoff³, Lan Wu², Olcay Y. Jones^1,4, Rodolfo Curiel¹, Frederick W. Miller² and Lisa G. Rider^1,2, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ³University of Oklahoma, Oklahoma City, OK, ⁴Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Clinically Amyopathic Juvenile Dermatomyositis (CAJDM) is a distinct clinical phenotype of JDM in which patients (pts) often have characteristic JDM rashes with little…
Abstract Number: 1370 • 2016 ACR/ARHP Annual Meeting
Development and Validation of a Composite Disease Activity Score for Juvenile Dermatomyositis
Silvia Rosina¹, Alessandro Consolaro¹, Pieter van Dijkhuizen¹, Kiran Nistala², Nicola Ruperto¹, Clarissa Pilkington³ and Angelo Ravelli¹, ¹Rheumatology, Giannina Gaslini Institute, Genova, Italy, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Paediatric Rheumatology, Great Ormond Street Hospital NHS Trust, London, United Kingdom
Background/Purpose: JDM is a multisystem vasculopathic disease that primarily affects the skin and muscles. Most tools for assessment of disease activity in JDM are lenghty,…
Abstract Number: 1371 • 2016 ACR/ARHP Annual Meeting
Comparison of Patient and Physician Reported Global Disease Activity Measures in Juvenile Dermatomyositis
Heather Tory¹, David Zurakowski², Susan Kim³ and CARRA JDM Quality Measures Workgroup, ¹Rheumatology, Connecticut Children's Medical Center, Hartford, CT, ²Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Patient reported outcomes (PROs) are becoming increasingly recognized as important in the care of patients with chronic diseases, such as Juvenile Dermatomyositis (JDM); however,…
Abstract Number: 1372 • 2016 ACR/ARHP Annual Meeting
Comparison of the Printo 2010 and Printo/International Myositis and Clinical Studies Group (IMACS) 2016 Improvement Criteria in the Printo Trial in New Onset Juvenile Dermatomyositis
Gabriella Giancane¹, Claudio Lavarello¹, Angela Pistorio¹, Lisa G. Rider¹, Rohit Aggarwal¹, Sheila Oliveira¹, Rubén J. Cuttica¹, Michel Fischbach², Gary Sterba¹, Karine Brochard², Frank Dressler¹, Patrizia Barone¹, Rubén Burgos-Vargas¹, Elizabeth C. Chalom¹, Marine Desjonqueres¹, Graciela Espada¹, Anders Fasth¹, Stella M. Garay¹, Rose-Marie Herbigneaux¹, Claire Hoyoux¹, Chantal Job-deslandre¹, Frederick W. Miller¹, Jiri Vencovsky¹, Angelo Ravelli³, Alberto Martini³ and Nicolino Ruperto⁴, ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, GENOA, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease characterized by chronic skeletal muscle inflammation with weakness and skin involvement. The Paediatric Rheumatology INternational…
Abstract Number: 1373 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
Janice Tiao^1,2, Rui Feng³, Emily M. Berger⁴, John F. Brandsema⁵, Carrie C. Coughlin⁶, Neelam Khan², Elizabeth A. Kichula⁵, Melissa A. Lerman⁷, Svetlana Lvovich⁸, Patrick J. McMahon⁹, Lisa G. Rider¹⁰, Adam I. Rubin², Lisabeth V. Scalzi¹¹, Douglas M. Smith⁵, Alysha J. Taxter¹², James R. Treat⁹, Ryan P. Williams¹³, Sabrina W. Yum⁵, Joyce Okawa² and Victoria P. Werth^1,2, ¹Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Division of Dermatology, Washington University School of Medicine, St. Louis, MO, ⁷Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁸St. Christopher's Hospital for Children, Philadelphia, PA, ⁹Division of Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Environmental Autoimmunity Group, Program of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, ¹¹Department of Rheumatology, Penn State Hershey Children’s Hospital, Hershey, PA, ¹²Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center, Winston-Salem, NC, ¹³Minneapolis Clinic of Neurology, Maple Grove, MN
Background/Purpose: The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool-Binary Method (CAT-BM) have been shown to be reliable and valid outcome…
Abstract Number: 1374 • 2016 ACR/ARHP Annual Meeting
Predictors of Changes in Disease Activity Among Children with Juvenile Dermatomyositis
Cynthia S. Crowson¹, Jeannette M. Olazagasti Lourido², Timothy B. Niewold³, Ann M Reed⁴ and CARRA Investigators, ¹Health Sciences Research, Mayo Clinic, Rochester, MN, ²University of Puerto Rico, San Juan, Puerto Rico, ³Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Duke University, Durham, NC
Background/Purpose: Determinants of changes in disease activity among patients with juvenile dermatomyositis (JDM) are unknown. Our objective was to develop scores to predict changes in…
Abstract Number: 1375 • 2016 ACR/ARHP Annual Meeting
A Five Year Study of 102 Children with Juvenile Myositis: Disease Course and Outcomes
Lauren M. Pachman^1,2,3, Megan L. Curran⁴, Gabrielle A. Morgan^5,6, Maria C. Amoruso^1,7, Ira N. Targoff^8,9 and Chiang-Ching Huang¹⁰, ¹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL, ⁴Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁶Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹University of Oklahoma, Oklahoma City, OK, ¹⁰Zilber School of Public Health, University of Wisconsin, Milwaukee, Milwaukee, WI
Background/Purpose: Children with juvenile myositis (JM) have a variable disease course, in part associated with myositis specific/associated antibodies (MSA). Time to off medications has not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].